Shares of LeMaitre Vascular Inc (NASDAQ:LMAT) have earned a consensus recommendation of “Hold” from the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $37.33.

Several analysts recently weighed in on LMAT shares. BidaskClub upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, March 9th. Benchmark upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Thursday, April 26th. Zacks Investment Research lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, April 28th. ValuEngine upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Friday, June 15th. Finally, Lake Street Capital began coverage on LeMaitre Vascular in a research note on Monday, June 25th. They issued a “buy” rating and a $45.00 target price on the stock.

In other news, insider Trent G. Kamke sold 12,368 shares of the stock in a transaction on Friday, May 25th. The stock was sold at an average price of $32.83, for a total transaction of $406,041.44. Following the transaction, the insider now owns 20,424 shares of the company’s stock, valued at approximately $670,519.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO George W. Lemaitre sold 8,000 shares of the stock in a transaction on Friday, June 15th. The stock was sold at an average price of $37.04, for a total value of $296,320.00. Following the transaction, the chief executive officer now directly owns 3,073,802 shares in the company, valued at approximately $113,853,626.08. The disclosure for this sale can be found here. In the last quarter, insiders sold 120,598 shares of company stock worth $4,144,663. Insiders own 20.30% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of LMAT. Victory Capital Management Inc. grew its position in shares of LeMaitre Vascular by 73.8% during the 1st quarter. Victory Capital Management Inc. now owns 5,076 shares of the medical instruments supplier’s stock worth $184,000 after buying an additional 2,156 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of LeMaitre Vascular during the 1st quarter worth $215,000. Advisor Group Inc. grew its position in shares of LeMaitre Vascular by 28.3% during the 4th quarter. Advisor Group Inc. now owns 7,033 shares of the medical instruments supplier’s stock worth $223,000 after buying an additional 1,550 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of LeMaitre Vascular during the 1st quarter worth $241,000. Finally, MetLife Investment Advisors LLC bought a new position in shares of LeMaitre Vascular during the 4th quarter worth $244,000. 72.87% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:LMAT opened at $35.76 on Wednesday. LeMaitre Vascular has a fifty-two week low of $26.37 and a fifty-two week high of $41.28. The firm has a market cap of $646.58 million, a P/E ratio of 41.58, a P/E/G ratio of 2.05 and a beta of 0.57.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Wednesday, April 25th. The medical instruments supplier reported $0.19 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.21 by ($0.02). LeMaitre Vascular had a net margin of 17.34% and a return on equity of 16.66%. The company had revenue of $25.99 million for the quarter, compared to analysts’ expectations of $26.42 million. During the same quarter in the previous year, the company posted $0.16 EPS. The business’s quarterly revenue was up 7.8% on a year-over-year basis. equities analysts forecast that LeMaitre Vascular will post 1.09 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 7th. Shareholders of record on Tuesday, May 22nd were paid a $0.07 dividend. The ex-dividend date of this dividend was Monday, May 21st. This represents a $0.28 dividend on an annualized basis and a yield of 0.78%. LeMaitre Vascular’s payout ratio is 32.56%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.